Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cabozantinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 0.94 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 0.94 |
| ▸ | AXL | P30530 | 12/20 | 0.94 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.94 |
| ▸ | MERTK | Q12866 | 3/20 | 0.94 |
| ▸ | FLT1 | P17948 | 3/20 | 0.94 |
| ▸ | FLT3 | P36888 | 2/20 | 0.94 |
| ▸ | AURKA | O14965 | 1/20 | 0.94 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | ABL1 | P00519 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.94 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.94 |
| ▸ | LCK | P06239 | 1/20 | 0.94 |
| ▸ | PGR | P06401 | 1/20 | 0.94 |
| ▸ | LYN | P07948 | 1/20 | 0.94 |
| ▸ | RET | P07949 | 1/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.94 |
| ▸ | HCK | P08631 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabozantinib SCHEMBL29351408 | 0.97 | AXL (1.00) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL29728791 | 0.97 | AXL (1.00) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL360795 | 0.97 | AXL (1.00) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL29195419 | 0.96 | AXL (0.91) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL18095042 | 0.96 | AXL (0.98) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL18097904 | 0.94 | AXL (0.90) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL27230101 | 0.94 | AXL (0.90) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL30979960 | 0.94 | AXL (0.90) | AXLMETAURKBMERTKKDR | |
| Cabozantinib SCHEMBL18095040 | 0.94 | AXL (0.93) | AXLMETAURKBMERTKKDR | |
| SCHEMBL30692003 | 0.94 | AXL (0.93) | AXLMETAURKBMERTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3274333-B1 | CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS | SANDOZ AG (CH) | 2019-04-24 | — | — | EP | claimed |
| EP-3274333-A1 | CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS | Sandoz AG (CH) | 2018-01-31 | — | — | EP | claimed |
| WO-2016150963-A1 | CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS | SANDOZ AG (CH) | 2016-09-29 | — | — | WO | claimed |
| EP-3274333-B1 | CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS | SANDOZ AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-10206916-B2 | Cabozantinib salts and their use as anti-cancer agents | SANDOZ AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20180110769-A1 | Cabozantinib Salts And Their Use As Anti-Cancer Agents | SANDOZ AG (CH) | 2018-04-26 | — | — | US | disclosed |
| EP-3274333-A1 | CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS | Sandoz AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016150963-A1 | CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS | SANDOZ AG (CH) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110769-A1 | Cabozantinib Salts And Their Use As Anti-Cancer Agents | TP53, CA5A, RCC1 | MET 97/4885KDR 288/4885AXL 338/4885 |
| US-10206916-B2 | Cabozantinib salts and their use as anti-cancer agents | TP53, CA5A, RCC1 | MET 97/4885KDR 288/4885AXL 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.